Board of directors

Thomas Pollare
Thomas Pollare
Chairman and member of the board since 2017.

Born: 1953

Education/experience: Thomas Pollare holds an M.D. from Karolinska Institutet and a Ph.D. from Uppsala university. He was previously a partner in the Venture Capital company 3i. He has held VP positions in both Pharmacia Corp and Schering-Plough Inc. He has been responsible for the market approval of several pharmaceutical products in various therapeutic areas and which generated billions in annual sales. He has previous experience of board work in start-up companies and private equity investments alike.

Current assignments: Chairman of the Board and CEO of Oncolution AB. Chairman of the Boards of AC Intressenter AB, Sinfonia Biotherapeutics AB, AlzeCure Discovery AB and Stiftelsen AlzeCure. Member of the boards of SSI Diagnostics Holding A/S, Bio-Works Technologies AB, Pharmaceuticals Sales & Development Sweden AB and Psilox AB. Alternate board member in Bio-Works Sweden AB.

Completed assignments (past five years): Chairman of the boards of Bio-Works Technologies AB, QuiaPEG Pharmaceuticals AB and QuiaPEG Pharmaceuticals Holding AB. Member of the boards of Cereno Scientific AB, Premacure Holding AB, Premacure AB, Xellia Pharmaceuticals ApS, Centro Gamma Knife Santiago S.a.P Chile, Gamma Knife Center Ecuador S.A, PT GammaKnife Center Indonesia, Cancun Oncology Center S.A.P.I de C.V Mexico, Center de Neuro-radiocirurgia Gamma Knife San Javier S.A de C.V Mexico, Center Oncologico y de Radioterapia TEC 100 S.A.P.I de C.V Mexico, Centro Gamma Knife Domnicana S.R.L. and Sweden Ghana Medical Center Ltd. CEO of Global Medical Investments GMI AB.

Holding: 801,887 shares and 35,000 share options.

Dependent in relation to the company and company management, but independent in relation to the company’s largest shareholders.

Ellen Donnelly
Ellen Donnelly
Board member since 2018.

Born: 1974

Education/experience: Ellen Donnelly has a Ph.D. from Yale University Medical School (USA). Ellen has previously held various executive positions in clinical development, project management, research and strategy at Pfizer. Prior to joining Pfizer, Ellen held various positions in American biotechnology and management consultancy companies.

Current assignment: CEO of Modus Therapeutics Holding AB (publ) and Modus Therapeutics AB.

Completed assignments (past five years): None.

Holding: No shareholding.

Independent in relation to the company, company management and the company’s major shareholders

An van Es-Johansson
An van Es-Johansson
Board member since 2017.

Born: 1960

Education/Experience: An van Es-Johansson has a M.D., Physician from Erasmus University, Rotterdam An has held several management positions within clinical development, medical affairs, business development and commercial at Sobi, Eli Lilly, Roche, Pharmacia & Upjohn and Biotech companies in USA, Holland, Schweiz and Sweden. She is an entrepreneur and mentor/coach and has a broad expertise within the industry.

Current assignments: Member of the board of Van Es Consulting AB, BioInvent International AB, Medivir AB and Agendia BV.

Completed assignments (last five years): VP Medical Affairs i Swedish Orphan Biovitrum AB.

Holding: 82,000 shares and 25,000 share options.

Dependent in relation to the company and company management, but independent in relation to the company’s largest shareholders.

Ragnar Linder
Ragnar Linder
Board member since 2017.

Born: 1953

Education/experience: Ragnar Linder has a civil engineering degree in chemical technology from the Royal School of Technology. Ragnar is a co-founder of Pygargus, a research company within the Real World Evidence area, that was acquired by IMS Health (now IQVIA) in 2013 and where Ragnar since then have held leading positions. Ragnar has also held several leading positions at Amgen Nordic (CEO), Aventis, HMR and Hoechst. In addition, Ragnar has been a member of the board of several biotech, pharmaceutical and CRO companies. Ragnar is currently an independent consultant.

Current assignments: Member of the board of R. Linder Holding AB and Pharmacolog in Uppsala AB.

Completed assignments (last five years): Member of the board of Umecrine Cognition AB and Pygargus AB.

Holding: 5,429 shares and 25,000 share options.

Independent in relation to the company, company management and the company’s major shareholders.

Pirkko Sulila Tamsen
Pirkko Sulila Tamsen
Board member since 2018.

Born: 1959

Education/experience: Pirkko Sulila Tamsen has a Ph.D. in zoophysiology from Uppsala University and an MSc in biology and chemistry from Uppsala University. Pirkko is an owner and consultant in Arandi Innovation AB, a member of the boards of Örebro Universitet Holding AB and start-up companies originating from academic research. Pirkko has many years’ experience from major pharmaceutical companies as Astra (now Astra Zenica) and Kabi (now Pfizer), as CEO and partner in a clinical contract research company and from development and innovation companies in the pharmaceutical sector. Pirkko was previously the CEO of Dilaforette AB (currently Modus Therapeutics) and Head of Uppsala University Innovation (UU Innovation).

Current assignment: Member of the boards of Örebro Universitet Holding AB, Örebro Universitet Uppdrag AB, Örebro Universitet Enterprise AB, HepaPredict AB and C26 Bioscience AB. Chairman of the Board and CEO at Arandi Innovation AB. Alternate member of the board and deputy CEO at Arandi Development AB.

Completed assignments (past five years): Chairman of the Board of Curenc AB and Rapp AB. Member of the boards of Karolinska Institutet Innovations AB and Uppsala University Innovation Tools AB. CEO at Dilaforette AB and NovaSAID AB

Holding: 11,000 shares and 25,000 share options.

Independent in relation to the company, company management and the company’s major shareholders.

Holdings in AlzeCure Pharma AB as of September 30, 2019.